"Aged, 80 and over" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A person 80 years of age and older.
| Descriptor ID |
D000369
|
| MeSH Number(s) |
M01.060.116.100.080
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aged, 80 and over".
Below are MeSH descriptors whose meaning is more specific than "Aged, 80 and over".
This graph shows the total number of publications written about "Aged, 80 and over" by people in this website by year, and whether "Aged, 80 and over" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 41 | 41 |
| 1996 | 0 | 45 | 45 |
| 1997 | 0 | 54 | 54 |
| 1998 | 0 | 53 | 53 |
| 1999 | 0 | 57 | 57 |
| 2000 | 0 | 60 | 60 |
| 2001 | 1 | 65 | 66 |
| 2002 | 0 | 97 | 97 |
| 2003 | 0 | 122 | 122 |
| 2004 | 1 | 114 | 115 |
| 2005 | 0 | 123 | 123 |
| 2006 | 0 | 143 | 143 |
| 2007 | 0 | 136 | 136 |
| 2008 | 0 | 194 | 194 |
| 2009 | 0 | 175 | 175 |
| 2010 | 0 | 172 | 172 |
| 2011 | 0 | 220 | 220 |
| 2012 | 0 | 238 | 238 |
| 2013 | 0 | 268 | 268 |
| 2014 | 0 | 264 | 264 |
| 2015 | 1 | 269 | 270 |
| 2016 | 0 | 299 | 299 |
| 2017 | 0 | 266 | 266 |
| 2018 | 0 | 318 | 318 |
| 2019 | 0 | 306 | 306 |
| 2020 | 0 | 274 | 274 |
| 2021 | 0 | 195 | 195 |
| 2022 | 0 | 62 | 62 |
| 2023 | 0 | 54 | 54 |
| 2024 | 0 | 205 | 205 |
| 2025 | 0 | 19 | 19 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aged, 80 and over" by people in Profiles.
-
BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial. J Cachexia Sarcopenia Muscle. 2025 Apr; 16(2):e13750.
-
Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2025 Mar 17; 31(6):965-974.
-
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025 Mar 13; 145(11):1126-1135.
-
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium. Blood Adv. 2025 Mar 11; 9(5):1013-1023.
-
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025 Mar 11; 9(5):1232-1241.
-
Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825. Neuro Oncol. 2025 Mar 07; 27(3):767-778.
-
Clinical Performance of an N-Terminal Pro-B-Type Natriuretic Peptide Assay in Acute Heart Failure Diagnosis. J Appl Lab Med. 2025 Mar 03; 10(2):325-338.
-
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy. Haematologica. 2025 Mar 01; 110(3):608-620.
-
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Haematologica. 2025 Mar 01; 110(3):706-714.
-
Anticipation, perception, and recollection of acute pain from local anesthesia injection prior to Mohs surgery. Arch Dermatol Res. 2025 Feb 25; 317(1):490.